Vanguard Group Inc Akebia Therapeutics, Inc. Transaction History
Vanguard Group Inc
- $4.96 Trillion
- Q1 2024
A detailed history of Vanguard Group Inc transactions in Akebia Therapeutics, Inc. stock. As of the latest transaction made, Vanguard Group Inc holds 8,225,972 shares of AKBA stock, worth $8.39 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
8,225,972
Previous 7,607,472
8.13%
Holding current value
$8.39 Million
Previous $9.43 Million
59.58%
% of portfolio
0.0%
Previous 0.0%
Shares
12 transactions
Others Institutions Holding AKBA
# of Institutions
127Shares Held
56.7MCall Options Held
937KPut Options Held
743K-
Satter Management Co., L.P.13.2MShares$13.5 Million26.98% of portfolio
-
Acadian Asset Management LLC Boston, MA5.31MShares$5.42 Million0.03% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny3.65MShares$3.73 Million0.01% of portfolio
-
Israel Englander Millennium Management LLC | New York, Ny3.27MShares$3.33 Million0.0% of portfolio
-
Black Rock Inc. New York, NY2.54MShares$2.59 Million0.0% of portfolio
About Akebia Therapeutics, Inc.
- Ticker AKBA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 183,848,992
- Market Cap $188M
- Description
- Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is vadadustat, an oral therapy, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) ...